Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

1-2-3 Project: A Quality Improvement Initiative to Normalize and Systematize Palliative Care for All Patients With Cancer in the Outpatient Clinic Setting.

Desai AV, Klimek VM, Chow K, Epstein AS, Bernal C, Anderson K, Okpako M, Rawlins-Duell R, Kramer D, Romano D, Goldberg JI, Nelson JE.

J Oncol Pract. 2018 Dec;14(12):e775-e785. doi: 10.1200/JOP.18.00346.

PMID:
30537456
2.

End-of-life care for older AML patients relapsing after allogeneic stem cell transplant at a dedicated cancer center.

Lin RJ, Elko TA, Perales MA, Alexander K, Jakubowski AA, Devlin SM, Dahi PB, Papadopoulos EB, Klimek VM, Giralt SA, Nelson JE.

Bone Marrow Transplant. 2018 Aug 22. doi: 10.1038/s41409-018-0311-5. [Epub ahead of print]

PMID:
30135464
3.

Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Pigneux A, Horst HA, Récher C, Klimek VM, Cortes JE, Carella AM, Egyed M, Krug U, Fox JA, Craig AR, Ward R, Smith JA, Acton G, Kantarjian HM, Stuart RK.

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24. No abstract available.

4.

Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.

Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, Berman E, Tallman MS, Frattini MG, Papanicolaou GA.

J Infect. 2018 Sep;77(3):227-234. doi: 10.1016/j.jinf.2018.03.015. Epub 2018 May 7.

PMID:
29746955
5.

The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells.

Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, MacKay M, Schulman J, Famulare C, Patel M, Klimek VM, Garrett-Bakelman FE, Melnick A, Carroll M, Mason CE, Jaffrey SR, Kharas MG.

Nat Med. 2017 Nov;23(11):1369-1376. doi: 10.1038/nm.4416. Epub 2017 Sep 18.

6.

Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.

Kotini AG, Chang CJ, Chow A, Yuan H, Ho TC, Wang T, Vora S, Solovyov A, Husser C, Olszewska M, Teruya-Feldstein J, Perumal D, Klimek VM, Spyridonidis A, Rampal RK, Silverman L, Reddy EP, Papaemmanuil E, Parekh S, Greenbaum BD, Leslie CS, Kharas MG, Papapetrou EP.

Cell Stem Cell. 2017 Mar 2;20(3):315-328.e7. doi: 10.1016/j.stem.2017.01.009. Epub 2017 Feb 16.

7.

CD99 is a therapeutic target on disease stem cells in myeloid malignancies.

Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, Levine RL, Carroll M, Klimek VM, Melnick AM, Park CY.

Sci Transl Med. 2017 Jan 25;9(374). pii: eaaj2025. doi: 10.1126/scitranslmed.aaj2025.

8.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Greenberg PL, Stone RM, Al-Kali A, Barta SK, Bejar R, Bennett JM, Carraway H, De Castro CM, Deeg HJ, DeZern AE, Fathi AT, Frankfurt O, Gaensler K, Garcia-Manero G, Griffiths EA, Head D, Horsfall R, Johnson RA, Juckett M, Klimek VM, Komrokji R, Kujawski LA, Maness LJ, O'Donnell MR, Pollyea DA, Shami PJ, Stein BL, Walker AR, Westervelt P, Zeidan A, Shead DA, Smith C.

J Natl Compr Canc Netw. 2017 Jan;15(1):60-87.

PMID:
28040720
9.

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.

Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F.

Haematologica. 2016 Nov;101(11):e457-e460. Epub 2016 Jul 14. No abstract available.

10.

MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.

Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ, Verma A, Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG.

Nat Commun. 2016 Feb 22;7:10739. doi: 10.1038/ncomms10739.

11.

Therapy-related myeloid neoplasms: what's in a name?

Klimek VM, Tray NJ.

Curr Opin Hematol. 2016 Mar;23(2):161-6. doi: 10.1097/MOH.0000000000000222. Review.

PMID:
26779614
12.

Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM.

Lancet Oncol. 2015 Sep;16(9):1025-1036. doi: 10.1016/S1470-2045(15)00201-6. Epub 2015 Jul 30.

13.

Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells.

Kotini AG, Chang CJ, Boussaad I, Delrow JJ, Dolezal EK, Nagulapally AB, Perna F, Fishbein GA, Klimek VM, Hawkins RD, Huangfu D, Murry CE, Graubert T, Nimer SD, Papapetrou EP.

Nat Biotechnol. 2015 Jun;33(6):646-55. doi: 10.1038/nbt.3178. Epub 2015 Mar 23.

14.

Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study.

Wesa KM, Cunningham-Rundles S, Klimek VM, Vertosick E, Coleton MI, Yeung KS, Lin H, Nimer S, Cassileth BR.

Cancer Immunol Immunother. 2015 Feb;64(2):237-47. doi: 10.1007/s00262-014-1628-6. Epub 2014 Oct 29.

15.

Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Abdel-Wahab O, Klimek VM, Gaskell AA, Viale A, Cheng D, Kim E, Rampal R, Bluth M, Harding JJ, Callahan MK, Merghoub T, Berger MF, Solit DB, Rosen N, Levine RL, Chapman PB.

Cancer Discov. 2014 May;4(5):538-45. doi: 10.1158/2159-8290.CD-13-1038. Epub 2014 Mar 3.

16.

Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.

Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, Nimer SD, Levine RL, Klimek VM.

Haematologica. 2013 Jun;98(6):908-12. doi: 10.3324/haematol.2012.076729. Epub 2013 Jan 24.

17.

Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia.

Klimek VM.

Curr Opin Hematol. 2013 Mar;20(2):137-43. doi: 10.1097/MOH.0b013e32835d82e6. Review.

PMID:
23343830
18.

Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia.

Baljevic M, Abdel-Wahab O, Rampal R, Maslak PG, Klimek VM, Rosenblat TL, Douer D, Levine RL, Tallman MS.

Acta Haematol. 2013;129(1):48-54. doi: 10.1159/000342493. Epub 2012 Nov 7.

PMID:
23147462
19.

Progression of RAS-mutant leukemia during RAF inhibitor treatment.

Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T, Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB.

N Engl J Med. 2012 Dec 13;367(24):2316-21. doi: 10.1056/NEJMoa1208958. Epub 2012 Nov 7.

20.

Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes.

Klimek VM, Dolezal EK, Tees MT, Devlin SM, Stein K, Romero A, Nimer SD.

Leuk Res. 2012 Sep;36(9):1093-7. doi: 10.1016/j.leukres.2012.04.025. Epub 2012 May 17.

PMID:
22608310
21.

It dices, it splices!

Klimek VM.

Blood. 2011 Dec 8;118(24):6237-8. doi: 10.1182/blood-2011-10-386540. No abstract available.

22.

Phase I trial of sodium salicylate in patients with myelodysplastic syndromes and acute myelogenous leukemia.

Klimek VM, Dolezal EK, Smith L, Soff G, Nimer SD.

Leuk Res. 2012 May;36(5):570-4. doi: 10.1016/j.leukres.2011.10.023. Epub 2011 Dec 9.

PMID:
22154022
23.

Hypomethylating agents in acute lymphoblastic leukemia: untapped potential?

Klimek VM, Tallman MS.

Leuk Lymphoma. 2011 Jan;52(1):7-8. doi: 10.3109/10428194.2010.524330. Epub 2010 Oct 7. No abstract available.

PMID:
20929335
24.

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, Klimek VM, Nimer SD, Gilliland DG, Dutreix C, Huntsman-Labed A, Virkus J, Giles FJ.

J Clin Oncol. 2010 Oct 1;28(28):4339-45. doi: 10.1200/JCO.2010.28.9678. Epub 2010 Aug 23.

25.

High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.

Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM, Boruchov A, Kewalramani T, Reich L, Nimer SD, Comenzo RL.

Bone Marrow Transplant. 2008 Sep;42(6):405-12. doi: 10.1038/bmt.2008.179. Epub 2008 Jun 23.

PMID:
18574442
26.

Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes.

Klimek VM, Fircanis S, Maslak P, Guernah I, Baum M, Wu N, Panageas K, Wright JJ, Pandolfi PP, Nimer SD.

Clin Cancer Res. 2008 Feb 1;14(3):826-32. doi: 10.1158/1078-0432.CCR-07-0318.

27.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.

Raza A, Reeves JA, Feldman EJ, Dewald GW, Bennett JM, Deeg HJ, Dreisbach L, Schiffer CA, Stone RM, Greenberg PL, Curtin PT, Klimek VM, Shammo JM, Thomas D, Knight RD, Schmidt M, Wride K, Zeldis JB, List AF.

Blood. 2008 Jan 1;111(1):86-93. Epub 2007 Sep 24.

28.

Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.

Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL.

Br J Haematol. 2006 Jan;132(2):155-61.

PMID:
16398649
29.

Serum levels of melanoma-inhibiting activity do not predict relapse in melanoma patients.

Klimek VM, Williams L, Chapman PB.

Cytokines Cell Mol Ther. 2002 Dec;7(2):71-4.

PMID:
12607797
30.

T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants.

Schaed SG, Klimek VM, Panageas KS, Musselli CM, Butterworth L, Hwu WJ, Livingston PO, Williams L, Lewis JJ, Houghton AN, Chapman PB.

Clin Cancer Res. 2002 May;8(5):967-72.

31.

Systemic chemotherapy.

Klimek VM, Wolchok JD, Chapman PB, Houghton AN, Hwu WJ.

Clin Plast Surg. 2000 Jul;27(3):451-61, ix-x. Review.

PMID:
10941565
32.

Supplemental Content

Loading ...
Support Center